for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018. In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash. In August 2020, the company announced it would acquire Cellero for $38 million in cash. In January 2021, the company announced it would acquire Distributed Bio, Inc. an antibody discovery business. In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million. In March 2021, Charles River announced the acquisition of Retrogenix for $48 million. In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million. In April 2022, the company announced it would acquire Explora BioLabs. In January 2023, the business announced it would acquire SAMDI Tech, Inc. See also List of S&P 500 companies Notes External links Companies listed on the New York Stock Exchange Health care companies established in 1947 Companies based in Wilmington, Massachusetts Multinational companies headquartered in the United States Animal rights Health care companies based in Massachusetts Contract research organizations Animal testing in the United States Animal testing in the United Kingdom 1947 establishments in Massachusetts Life sciences industry 2000 initial public offerings